Claims for Patent: RE38628

Summary for Patent: RE38628

Title:	Pharmaceutical compositions
Abstract:	A method of treatment of a condition selected from the group comprising conjunctivitis, keratitis, `allergic eyes`, adenovirus infections, corneal homograft rejection, anterior uveitis, nasal polyps, vasomotor rhinitis, allergic manifestations of the nasopharynx, reversible obstructive airways disease, Crohn's disease, distal colitis and proctitis, which method comprises administration to a patient suffering from such a condition of a therapeutically effective amount of an aqueous solution containing, as active ingredient, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dica rboxylic acid or a pharmaceutically acceptable salt thereof. Also described are novel pharmaceutical compositions suitable for use in such methods of treatment.
Inventor(s):	Clark; Andrew R. (Half Moon Bay, CA), Wright; Paul (Bramcote, GB), Ratcliffe; Julia H. (Woodbridge, GB)
Assignee:	Fisons plc (Ipswich, GB)
Application Number:	08/916,578
Patent Claims:	1. A method of treating a reversible obstructive airways disease comprising administering, by inhalation, to a patient suffering from, or susceptible to, such a condition the nebulized contents of an ampoule of carbon dioxide permeable plastics material filled with a unit dose of an aqueous pharmaceutical solution containing, as active ingredient, from 0.1 to 5% w/v of 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dica rboxylic acid or a pharmaceutically acceptable salt thereof, the solution having a pH of 3.5 to 6.0. 2. The method of treatment according to claim 1, wherein the concentration of the active ingredient in the solution is from 0.1 to 1.0% w/v. 3. The method of treatment according to claim 1, wherein the active ingredient is nedocromil sodium..Iadd. 4. A method of controlling the symptoms of conjunctivitis comprising administering to the eye of a patient having conjunctivitis an effective amount of nedocromil sodium in an ophthalmically acceptable formulation..Iaddend..Iadd. 5. The method of claim 4, wherein the conjunctivitis is vernal conjunctivitis..Iaddend..Iadd. 6. The method of claim 4, wherein the conjunctivitis is allergic conjunctivitis..Iaddend..Iadd. 7. The method of claim 4, wherein the conjunctivitis is seasonal allergic conjunctivitis..Iaddend..Iadd. 8. A method of treatment of a disease selected from the group consisting of conjunctivitis, keratitis, allergic eyes, and anterior uveitis, which method comprises administering to the eye an effective amount of an ophthalmically acceptable aqueous pharmaceutical solution containing the active ingredient 9-ethyl-6,-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2g)quinoline-2,8-dicarb oxylic acid, or a pharmaceutically acceptable salt thereof..Iaddend..Iadd. 9. The method of claim 8, wherein the disease is conjunctivitis..Iaddend..Iadd. 10. The method of claim 9, wherein the disease is seasonal allergic conjunctivitis..Iaddend..Iadd. 11. The method of claim 9, wherein the disease is allergic conjunctivitis..Iaddend..Iadd. 12. The method of claim 9, wherein the disease is vernal conjunctivitis..Iaddend..Iadd. 13. The method of claims 8, 9, 10, 11 or 12, wherein said active ingredient is nedocromil sodium..Iaddend.